Oncology Requisition	
ACCOUNT INFORMATION	2330 Inwood Road, Suite EB3.304 Dallas, Texas 75235 UTSouthwestern
Account name:	LAB PHONE: 214-648-0930 Medical Center
Address: City: State:	LAB FAX: 214-648-0940 CUSTOMER SERVICE: 214-633-5227
Zip code: Ph: Fax:	CLIA #: 45D-0861764 CLINICAL LABORATORY SERVICES CAP #: 2664213
•	OAI #. 2004210
REQUIRED ORDER INFORMATION Facility / Client Facility Clien	
BILL TO: Patient / 3rd party – Billing information must be provided	PATIENT/3RD PARTY BILLING INFORMATION
Patient Name: (Last, First, Middle)	ICD-10 Code(s)
	Medicare patients with non-covered diagnoses must sign Advanced Signed ABN
	Beneficiary Notice (ABN) available at www.veripathlabs.com or by calling customer service at 214-645-7057 or toll free 877-887-8136 included
Date of Birth: Sex: Patient ID / MR#:	ICD-10 Codes applicable to each and every test requested should come only from the ordering physician, represent the reason for the test order at the time of order, and be supported by the patient's medical record.
	Physicians should order only tests that are medically necessary for the diagnosis or treatment of the patient. Tests ordered should be single laboratory tests appropriate for the patient's medical condition. Tests for
Hospital Inpatient Y / N Collection Date: Collection Time: AM	screening purposes may be ordered, but may not be reimbursed.
Ordering Physician (Full Name): NPI:	Insured/Responsible Party Name: (if different from patient-Last, First, Middle) Date of Birth:
	Patient's relationship: Responsible Party Address: City:
Phone: Pager: FAX:	□ Self □ Spouse
Clinical Indication	□ Dependent □ Other Gender: State: Zip: Phone:
for Tests Ordered:	☐ Male ☐ Female
SPECIMEN INFORMATION	Employer's Name: Employer's Phone:
☐ Bone Marrow ☐ Peripheral Blood	Insurance Co. Name: Insurance Co. Phone:
☐ Bone Marrow Aspirate Smears ☐ Peripheral Blood Smears ☐ Bone Marrow Touch Prep	•
☐ Bone Marrow Core Biopsy ☐ Left ☐ Right	Insurance Co. Address:
☐ Urine ☐ CSF ☐ Body Fluid	Policy #: Group #:
□ Tissue: site/type □ Formalin Fixed Paraffin Embedded Tissue (FFPE)	Today ii.
Surgical Pathology/Cytology	□ Medicare □ HMO □ Other Member ID#:
Case Number:Block Number:	□ Medicaid □ PPO □ □ Date/Time:
Please see page 2 instructions	Name:
CLINICAL INFORMATION	TESTS REQUESTED (cont.)
Infection: HIV Hepatitis Other	Cytogenetics (Sodium Heparin preferred)
History : □ Lymphadenopathy □ Mediastinal Mass □ Splenomegaly	☐ Chromosomal Analysis ☐ FISH specify
Therapy: ☐ Chemotherapy ☐ Growth Factor	FISH
☐ Immunotherapy ☐ Other	☐ BIRC3/MALT1: t(11:18) ☐ IGH/BCL2: t(14;18) ☐ CLL
Status: ☐ Initial ☐ Relapse ☐ Remission ☐ Post Transplant ☐ Other	☐ BCL6:3g27 ☐ IGH/MAF.t(14,16) ☐ MM
TESTS REQUESTED	☐ BCR/ABL1: t(9;22) ☐ IGH/MAFB: t(14;20) ☐ MDS ☐ MDM2: 12q15 ☐ ALL
Morphology	\square CBFB: inv(16) \square MLL (KMT2A): 11g23 \square AML
☐ Bone Marrow Morphology exam ☐ Peripheral Blood exam	\square CCND1/IGH: t(11;14) \square MYC/IGH: t(8:14) \square Lymphoma
Flow Cytometry (ACD preferred) Attach Current CBC Report	☐ C-MET:7q31.2 ☐ MYCN: 2p23-24
☐ Leukemia/Lymphoma Immunophenotyping ☐ Leukemia/Lymphoma Immunophenotyping MRD	☐ Deletion/monosomy 5 ☐ MYC: 8q24
☐ PNH (Paroxysmal Nocturnal Hemoglobinuria)	☐ Deletion/monosomy 7 ☐ PDGFRB: 5q33.1 ☐ DDIT3: 12q13 ☐ PMI /PAPA: #(15:17)
☐ Leukemia/Lymphoma Immunophenotyping CART 19/Immunotherapy f/u	
☐ ALPS (Autoimmune Lymphoproliferative Syndrome)	□ TD1. 19914
☐ BAL (Bronchoalveolar Lavage) CD4:CD8	☐ EV6/RUNX1: t(12;21) ☐ RUNX1T1/RUNX1: t(8;21) ☐ EWSR1: 22q12 ☐ TFE-3: Xp11.2
☐ Leukemia/Lymphoma CSF (Cerebrospinal Fluid)	☐ FGFR1: 8p11.2 ☐ TFE-B: 6p21
☐ Leukemia/Lymphoma FLUID (Other Fluid, not CSF)	☐ FIP1L1/PDGFRA: 4q12 ☐ SS18: 18q11.2
 □ Process and hold - Client should call next day with instructions □ Other Markers: 	☐ FGFR3/IGH: t(4;14) ☐ TP53: 17p13.1
Molecular Diagnostics (EDTA preferred)	☐ FOXO1: 13q14 ☐ UroVysion ®
☐ B-cell Clonality PCR ☐ FLT3	☐ FUS: 16p11.2 ☐ Other FISH (please call lab)
☐ T-cell Clonality PCR ☐ KRAS	Lung Adenocarcinoma Panel (on FFPE Tissue)
 □ BRAF □ LOH 1p/19q □ EGFR □ NRAS 	Mutation Analysis (Molecular Diagnostics) ☐ EGFR ☐ KRas ☐ BRAF
□ ERBB2 □ PIK3CA	FISH Assay (Cytogenetics)
☐ IDH1/IDH2 ☐ T790M resistance EGFR	□ ALK □ RÓS1 □ RÉT □ C-MET □ Her-2
☐ ERBB2 ☐ CKIT (melanoma) ☐ IDH1/IDH2 ☐ Microsatellite instability by PCR	IHC Assay ☐ PTEN
☐ IDH1/IDH2 ☐ Microsatellite instability by PCR ☐ TP53	Transplant Analysis
Cancer Panels	☐ FISH - X/Y sex chromosomes
☐ Colon (KRAS, NRAS, and BRAF) ☐ Lung (EGFR, KRAS, BRAF, PIK3CA, AKT, ERBB2, NRAS, MEK)	☐ STR Pre-transplant analysis ☐ STR Post-transplant analysis
☐ Melanoma (BRAF, KIT, and NRAS)	☐ Donor Name: Recipient Name: Please provide dates of all previous transplants:
☐ 50-gene Cancer Mutation Panel by NGS	
LAB Transport Container: Total # of specimens:_	Transport Conditions: Destination: Other Initials:
USEYellowGreenPurpleSyringeConicalRedBlue ONLY Trans TubeBlockSlidesFormalinOther:	
ONLYTrans TubeBlockSlidesFormalinOther:	

ON-091019(1)

Sample Requirement for Unstained Slides from FFPE Tissue

If ordering on non-UT Southwestern/Parkland Pathology material, please include a copy of the Surgical Pathology/Cytopathology report, the block/unstained slides and corresponding H&E slide.

For UT Patients

Deliver to: Anatomic Pathology Central Receiving 6201 Harry Hines Blvd, D4.426

Dallas Texas 75235 Phone: 214-633-4100

Fax: 214-633-8854

For Parkland Patients

Deliver to: 5200 Harry Hines Dept. of Pathology, Room D2.625

Attn: Histology Dallas, TX. - 75235 Phone: 469-419-4478 Fax Number: 469-419-3027

Molecular Diagnostics

Test	Slide Requirements
EGFR Mutation	10 slides @ 10u, 1 H&E
KRAS, BRAF and EGFR	10 slides @ 10u, 1 H&E
50-Gene Panel	10 slides @ 10u, 1 H&E
Colon Panel (KRAS, BRAF, NRAS)	10 slides @ 10u, 1 H&E
Melanoma Panel (BRAF, cKIT, NRAS)	10 slides @ 10u, 1 H&E
KRAS or BRAF or IDH1/2	5 slides @ 10u, 1 H&E
KRAS and BRAF	5 slides @ 10u, 1 H&E
B cell or T cell Clonality	5 slides @ 10u, 1 H&E
B cell and T cell Clonality	5 slides @ 10u, 1 H&E
TP53	10 slides @ 10 microns
1p/19q LOH	3 slides @ 4u, 1 H&E

Cytogenetics

Test	Slide Requirements
ALK: 2p23 by FISH	2 positively charged slides @4u, 1 H&E
BCL6: 3q27 by FISH	2 positively charged slides @3u
C-MET: 7q31.2 by FISH	2 positively charged slides @4u, 1 H&E
CCND1/IGH by FISH	2 positively charged slides @3u
DDIT3: 12q13 by FISH	2 positively charged slides @4u, 1 H&E
EGFR: 7p12 by FISH	2 positively charged slides @4u, 1 H&E
EWSR1: 22q12 by FISH	2 positively charged slides @4u, 1 H&E
FGFR1: 8p12 by FISH	2 positively charged slides @4u, 1 H&E
FOXO1: 13q14 by FISH	2 positively charged slides @4u, 1 H&E
FUS: 16p11.2 by FISH	2 positively charged slides @4u, 1 H&E
MDM2: 12q15	2 positively charged slides @4u, 1 H&E
HER2/neu by FISH	2 positively charged slides @4u, 1 H&E
IGH/BCL2: t(14;18) by FISH	2 positively charged slides @3u
MYC/IGH: t(8;14) by FISH	2 positively charged slides @3u
MYC: 8q24 by FISH	2 positively charged slides @3u
MYCN: 2p23-24	2 positively charged slides @4u, 1 H&E
PDGFRA: 4q12 by FISH	2 positively charged slides @3u
PDGFRB: 5q33.1 by FISH	2 positively charged slides @3u
SS18: 18q11.2 by FISH	2 positively charged slides @4u, 1 H&E

Lung Adenocarcinoma Panel	10 slides @ 10u and 9 positivly charged slides @ 4u	
---------------------------	---	--